Contemporary Role of Systematic Prostate Biopsies: Indications, Techniques, and Implications for Patient Care

Graif, 2007, Under diagnosis and over diagnosis of prostate cancer, J Urol, 178, 88, 10.1016/j.juro.2007.03.017 Thompson, 2004, Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter, N Engl J Med, 350, 2239, 10.1056/NEJMoa031918 Brenner, 2005, Long-term survival rates of patients with prostate cancer in the prostate-specific antigen screening era: population-based estimates for the year 2000 by period analysis, J Clin Oncol, 23, 441, 10.1200/JCO.2005.11.148 Welch, 2010, Overdiagnosis in cancer, J Natl Cancer Inst, 102, 605, 10.1093/jnci/djq099 Presti, 2000, The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies: results of a prospective clinical trial, J Urol, 163, 163, 10.1016/S0022-5347(05)67995-5 Babaian, 2000, A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy, J Urol, 163, 152, 10.1016/S0022-5347(05)67993-1 Stewart, 2001, Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies, J Urol, 166, 86, 10.1016/S0022-5347(05)66083-1 San Francisco, 2003, Extended prostate needle biopsy improves concordance of Gleason grading between prostate needle biopsy and radical prostatectomy, J Urol, 169, 136, 10.1016/S0022-5347(05)64053-0 Presti, 2003, Extended peripheral zone biopsy schemes increase cancer detection rates and minimize variance in prostate specific antigen and age related cancer rates: results of a community multi-practice study, J Urol, 169, 125, 10.1016/S0022-5347(05)64051-7 Scattoni, 2007, Extended and saturation prostatic biopsy in the diagnosis and characterisation of prostate cancer: a critical analysis of the literature, Eur Urol, 52, 1309, 10.1016/j.eururo.2007.08.006 Numao, 2007, Improved accuracy in predicting the presence of Gleason pattern 4/5 prostate cancer by three-dimensional 26-core systematic biopsy, Eur Urol, 52, 1663, 10.1016/j.eururo.2007.01.025 Ploussard, 2009, The role of biopsy core number in selecting prostate cancer patients for active surveillance, Eur Urol, 56, 891, 10.1016/j.eururo.2009.07.053 Ploussard G, Marchand C, Nicolaiew N, et al. Prospective evaluation of an extended 21-core biopsy scheme as initial prostate cancer diagnostic strategy. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2012.05.049. Capitanio, 2009, Biopsy core number represents one of foremost predictors of clinically significant Gleason sum upgrading in patients with low-risk prostate cancer, Urology, 73, 1087, 10.1016/j.urology.2008.10.048 Okotie, 2007, Characteristics of prostate cancer detected by digital rectal examination only, Urology, 70, 1117, 10.1016/j.urology.2007.07.019 Schröder, 2012, Prostate-cancer mortality at 11 years of follow-up, N Engl J Med, 366, 981, 10.1056/NEJMoa1113135 Andriole, 2012, Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up, J Natl Cancer Inst, 104, 125, 10.1093/jnci/djr500 Roobol, 2010, A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer, Eur Urol, 57, 79, 10.1016/j.eururo.2009.08.025 Zhu, 2012, Risk-based prostate cancer screening, Eur Urol, 61, 652, 10.1016/j.eururo.2011.11.029 Carter, 2006, Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability, J Natl Cancer Inst, 98, 1521, 10.1093/jnci/djj410 NCCN Guidelines. Prostate cancer early detection [v.2.2012]. National Comprehensive Cancer Network Web site. http://www.nccn.org/professionals/physician_gls/pdf/prostate_detection.pdf. Vickers, 2009, Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer, J Clin Oncol, 27, 398, 10.1200/JCO.2008.18.1685 Catalona, 1998, Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial, JAMA, 279, 1542, 10.1001/jama.279.19.1542 Benson, 1992, Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer, J Urol, 147, 815, 10.1016/S0022-5347(17)37393-7 Catalona, 2000, Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging, Urology, 56, 255, 10.1016/S0090-4295(00)00637-3 Oesterling, 1993, Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges, JAMA, 270, 860, 10.1001/jama.1993.03510070082041 Morgan, 1996, Age-specific reference ranges for prostate-specific antigen in black men, N Engl J Med, 335, 304, 10.1056/NEJM199608013350502 Vickers, 2008, A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden, BMC Med, 6, 19, 10.1186/1741-7015-6-19 Vickers, 2010, Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication, J Clin Oncol, 28, 2493, 10.1200/JCO.2009.24.1968 Vickers, 2011, A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening, Cancer Epidemiol Biomarkers Prev, 20, 255, 10.1158/1055-9965.EPI-10-1003 Sokoll, 2008, [-2]Proenzyme prostate specific antigen for prostate cancer detection: a National Cancer Institute Early Detection Research Network validation study, J Urol, 180, 539, 10.1016/j.juro.2008.04.015 Le, 2010, [-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study, J Urol, 183, 1355, 10.1016/j.juro.2009.12.056 Guazzoni, 2011, Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting, Eur Urol, 60, 214, 10.1016/j.eururo.2011.03.052 Roobol, 2010, Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test, Eur Urol, 58, 475, 10.1016/j.eururo.2010.06.039 Perdonà, 2011, Prostate cancer detection in the “grey area” of prostate-specific antigen below 10 ng/ml: head-to-head comparison of the updated PCPT calculator and Chun's nomogram, two risk estimators incorporating prostate cancer antigen 3, Eur Urol, 59, 81, 10.1016/j.eururo.2010.09.036 de la Taille, 2011, Clinical evaluation of the PCA3 assay in guiding initial biopsy decisions, J Urol, 185, 2119, 10.1016/j.juro.2011.01.075 Ferro, 2012, Predicting prostate biopsy outcome: prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers, Clin Chim Acta, 413, 1274, 10.1016/j.cca.2012.04.017 Heidenreich, 2011, EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease, Eur Urol, 59, 61, 10.1016/j.eururo.2010.10.039 Gosselaar, 2008, The value of an additional hypoechoic lesion-directed biopsy core for detecting prostate cancer, BJU Int, 101, 685, 10.1111/j.1464-410X.2007.07309.x Toi, 2007, The continuing importance of transrectal ultrasound identification of prostatic lesions, J Urol, 177, 516, 10.1016/j.juro.2006.09.061 Trottier, 2011, Comparison of risk calculators from the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer in a contemporary Canadian cohort, BJU Int, 108, E237, 10.1111/j.1464-410X.2011.10207.x Dickinson, 2011, Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting, Eur Urol, 59, 477, 10.1016/j.eururo.2010.12.009 Villers, 2006, Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings, J Urol, 176, 2432, 10.1016/j.juro.2006.08.007 Villeirs, 2011, Combined magnetic resonance imaging and spectroscopy in the assessment of high grade prostate carcinoma in patients with elevated PSA: a single-institution experience of 356 patients, Eur J Radiol, 77, 340, 10.1016/j.ejrad.2009.08.007 Barentsz, 2012, ESUR prostate MR guidelines 2012, Eur Radiol, 22, 746, 10.1007/s00330-011-2377-y Bratt, 2010, Effects of prostate-specific antigen testing on familial prostate cancer risk estimates, J Natl Cancer Inst, 102, 1336, 10.1093/jnci/djq265 Andriole, 2010, Effect of dutasteride on the risk of prostate cancer, N Engl J Med, 362, 1192, 10.1056/NEJMoa0908127 Thomas, 2012, Prostate cancer risk in men with prostate and breast cancer family history: results from the REDUCE study (R1), J Intern Med, 272, 85, 10.1111/j.1365-2796.2011.02504.x Yanke, 2006, African-American race is a predictor of prostate cancer detection: incorporation into a pre-biopsy nomogram, BJU Int, 98, 783, 10.1111/j.1464-410X.2006.06388.x Hemmerich JA, Ahmad FS, Meltzer DO, Dale W. African American men significantly underestimate their risk of having prostate cancer at the time of biopsy. Psychooncology. In press. http://dx.doi.org/10.1002/pon.2098. Schröder, 2008, The comparability of models for predicting the risk of a positive prostate biopsy with prostate-specific antigen alone: a systematic review, Eur Urol, 54, 274, 10.1016/j.eururo.2008.05.022 Thompson, 2006, Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial, J Natl Cancer Inst, 98, 529, 10.1093/jnci/djj131 Hernandez, 2009, Predicting the outcome of prostate biopsy: comparison of a novel logistic regression-based model, the prostate cancer risk calculator, and prostate-specific antigen level alone, BJU Int, 103, 609, 10.1111/j.1464-410X.2008.08127.x Eyre, 2009, Validation in a multiple urology practice cohort of the Prostate Cancer Prevention Trial calculator for predicting prostate cancer detection, J Urol, 182, 2653, 10.1016/j.juro.2009.08.056 van Vugt, 2011, Prediction of prostate cancer in unscreened men: external validation of a risk calculator, Eur J Cancer, 47, 903, 10.1016/j.ejca.2010.11.012 Cavadas, 2010, Prostate Cancer Prevention Trial and European Randomized Study of Screening for Prostate Cancer Risk calculators: a performance comparison in a contemporary screened cohort, Eur Urol, 58, 551, 10.1016/j.eururo.2010.06.023 van Vugt, 2012, Prospective validation of a risk calculator which calculates the probability of a positive prostate biopsy in a contemporary clinical cohort, Eur J Cancer, 48, 1809, 10.1016/j.ejca.2012.02.002 Chun, 2007, Development and external validation of an extended repeat biopsy nomogram, J Urol, 177, 510, 10.1016/j.juro.2006.09.025 Nam, 2007, Assessing individual risk for prostate cancer, J Clin Oncol, 25, 3582, 10.1200/JCO.2007.10.6450 Zaytoun, 2011, Development of improved nomogram for prediction of outcome of initial prostate biopsy using readily available clinical information, Urology, 78, 392, 10.1016/j.urology.2011.04.042 Campos-Fernandes, 2009, Prostate cancer detection rate in patients with repeated extended 21-sample needle biopsy, Eur Urol, 55, 600, 10.1016/j.eururo.2008.06.043 Zaytoun, 2011, Office based transrectal saturation biopsy improves prostate cancer detection compared to extended biopsy in the repeat biopsy population, J Urol, 186, 850, 10.1016/j.juro.2011.04.069 Hambrock, 2010, Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen, J Urol, 183, 520, 10.1016/j.juro.2009.10.022 Mitterberger, 2007, Comparison of contrast enhanced color Doppler targeted biopsy to conventional systematic biopsy: impact on Gleason score, J Urol, 178, 464, 10.1016/j.juro.2007.03.107 Aigner, 2010, Value of real-time elastography targeted biopsy for prostate cancer detection in men with prostate specific antigen 1.25 ng/ml or greater and 4.00 ng/ml or less, J Urol, 184, 913, 10.1016/j.juro.2010.05.026 Miyagawa, 2010, Real-time virtual sonography for navigation during targeted prostate biopsy using magnetic resonance imaging data, Int J Urol, 17, 855, 10.1111/j.1442-2042.2010.02612.x Lemaitre, 2009, Dynamic contrast-enhanced MRI of anterior prostate cancer: morphometric assessment and correlation with radical prostatectomy findings, Eur Radiol, 19, 470, 10.1007/s00330-008-1153-0 Sumura, 2007, Initial evaluation of prostate cancer with real-time elastography based on step-section pathologic analysis after radical prostatectomy: a preliminary study, Int J Urol, 14, 811, 10.1111/j.1442-2042.2007.01829.x Progensa PCA3 assay. US Food and Drug Administration Web site. www.fda.gov/MedicalDevices/ucm294907.htm. Premarket approval letter for the Progensa PCA3 assay. US Food and Drug Administration Web site. http://www.accessdata.fda.gov/cdrh_docs/pdf10/p100033a.pdf. Deras, 2008, PCA3: a molecular urine assay for predicting prostate biopsy outcome, J Urol, 179, 1587, 10.1016/j.juro.2007.11.038 Haese, 2008, Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy, Eur Urol, 54, 1081, 10.1016/j.eururo.2008.06.071 Chun, 2009, Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram, Eur Urol, 56, 659, 10.1016/j.eururo.2009.03.029 Auprich, 2010, External validation of urinary PCA3-based nomograms to individually predict prostate biopsy outcome, Eur Urol, 58, 727, 10.1016/j.eururo.2010.06.038 Aubin, 2010, PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial, J Urol, 184, 1947, 10.1016/j.juro.2010.06.098 Auprich, 2011, Contemporary role of prostate cancer antigen 3 in the management of prostate cancer, Eur Urol, 60, 1045, 10.1016/j.eururo.2011.08.003 Ploussard, 2010, The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: does free-to-total prostate-specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies?, BJU Int, 106, 1143, 10.1111/j.1464-410X.2010.09286.x Auprich, 2012, A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy, BJU Int, 109, 1627, 10.1111/j.1464-410X.2011.10584.x Epstein, 2006, Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care, J Urol, 175, 820, 10.1016/S0022-5347(05)00337-X Chun, 2010, Optimizing performance and interpretation of prostate biopsy: a critical analysis of the literature, Eur Urol, 58, 851, 10.1016/j.eururo.2010.08.041 Ploussard, 2009, High-grade prostatic intraepithelial neoplasia and atypical small acinar proliferation on initial 21-core extended biopsy scheme: incidence and implications for patient care and surveillance, World J Urol, 27, 587, 10.1007/s00345-009-0413-1 Wolters, 2010, False-negative prostate needle biopsies: frequency, histopathology features, and follow-up, Am J Surg Pathos, 34, 35, 10.1097/PAS.0b013e3181c3ece9 Bostwick, 2012, Precursors of prostate cancer, Histopathology, 60, 4, 10.1111/j.1365-2559.2011.04007.x Merrimen, 2009, Multifocal high grade prostatic intraepithelial neoplasia is a significant risk factor for prostatic adenocarcinoma, J Urol, 182, 485, 10.1016/j.juro.2009.04.016 Godoy, 2011, Long-term follow-up of men with isolated high-grade prostatic intra-epithelial neoplasia followed by serial delayed interval biopsy, Urology, 77, 669, 10.1016/j.urology.2010.07.519 Hayes, 2010, Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis, JAMA, 304, 2373, 10.1001/jama.2010.1720 Berglund, 2008, Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance, J Urol, 180, 1964, 10.1016/j.juro.2008.07.051 Porten, 2011, Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance, J Clin Oncol, 29, 2795, 10.1200/JCO.2010.33.0134 Bul, 2012, Predictors of unfavourable repeat biopsy results in men participating in a prospective active surveillance program, Eur Urol, 61, 370, 10.1016/j.eururo.2011.06.027 Nakanishi, 2008, PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance, J Urol, 179, 1804, 10.1016/j.juro.2008.01.013 Ploussard, 2011, Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance, Eur Urol, 59, 422, 10.1016/j.eururo.2010.11.044 van Poppel, 2012, The relationship between prostate cancer gene 3 (PCA3) and prostate cancer significance, BJU Int, 109, 360, 10.1111/j.1464-410X.2011.10377.x Margel, 2012, Impact of multiparametric endorectal coil prostate magnetic resonance imaging on disease reclassification among active surveillance candidates: a prospective cohort study, J Urol, 187, 1247, 10.1016/j.juro.2011.11.112 Dahabreh, 2012, Active surveillance in men with localized prostate cancer: a systematic review, Ann Intern Med, 156, 582, 10.7326/0003-4819-156-8-201204170-00009 Duffield, 2009, Radical prostatectomy findings in patients in whom active surveillance of prostate cancer fails, J Urol, 182, 2274, 10.1016/j.juro.2009.07.024 Porten, 2011, Changes in cancer volume in serial biopsies of men on active surveillance for early stage prostate cancer, J Urol, 186, 1825, 10.1016/j.juro.2011.06.055 Fujita, 2009, Serial prostate biopsies are associated with an increased risk of erectile dysfunction in men with prostate cancer on active surveillance, J Urol, 182, 2664, 10.1016/j.juro.2009.08.044 Ross, 2010, Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program, J Clin Oncol, 28, 2810, 10.1200/JCO.2009.25.7311 van den Bergh, 2008, Prostate-specific antigen kinetics in clinical decision-making during active surveillance for early prostate cancer—a review, Eur Urol, 54, 505, 10.1016/j.eururo.2008.06.040 Tosoian, 2010, Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program, J Urol, 183, 534, 10.1016/j.juro.2009.10.003 Natarajan, 2011, Clinical application of a 3D ultrasound-guided prostate biopsy system, Urol Oncol, 29, 334, 10.1016/j.urolonc.2011.02.014 Baumann, 2012, Prostate biopsy tracking with deformation estimation, Med Image Anal, 16, 562, 10.1016/j.media.2011.01.008 Ukimura, 2011, Innovations in prostate biopsy strategies for active surveillance and focal therapy, Curr Opin Urol, 21, 115, 10.1097/MOU.0b013e3283435118 Hara, 2008, Optimal approach for prostate cancer detection as initial biopsy: prospective randomized study comparing transperineal versus transrectal systematic 12-core biopsy, Urology, 71, 191, 10.1016/j.urology.2007.09.029 Takenaka, 2008, A prospective randomized comparison of diagnostic efficacy between transperineal and transrectal 12-core prostate biopsy, Prostate Cancer Prostatic Dis, 11, 134, 10.1038/sj.pcan.4500985 Abdollah, 2011, Trans-rectal versus trans-perineal saturation rebiopsy of the prostate: is there a difference in cancer detection rate?, Urology, 77, 921, 10.1016/j.urology.2010.08.048 Hossack, 2012, Location and pathological characteristics of cancers in radical prostatectomy specimens identified by transperineal biopsy compared to transrectal biopsy, J Urol, 188, 781, 10.1016/j.juro.2012.05.006 Haas, 2007, Needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalence, J Natl Cancer Inst, 99, 1484, 10.1093/jnci/djm153 Wright, 2006, Improved prostate cancer detection with anterior apical prostate biopsies, Urol Oncol, 24, 492, 10.1016/j.urolonc.2006.03.003 Scattoni, 2002, Prostatic transrectal ultrasound (TRUS) guided biopsy schemes and TRUS prostatic lesion-guided biopsies, Eur Urol Suppl, 1, 28, 10.1016/S1569-9056(02)00054-4 Remzi, 2005, The Vienna nomogram: validation of a novel biopsy strategy defining the optimal number of cores based on patient age and total prostate volume, J Urol, 174, 1256, 10.1097/01.ju.0000173924.83392.cc Eichler, 2006, Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review, J Urol, 175, 1605, 10.1016/S0022-5347(05)00957-2 Jones, 2006, Saturation technique does not improve cancer detection as an initial prostate biopsy strategy, J Urol, 175, 485, 10.1016/S0022-5347(05)00211-9 Kawakami, 2007, Optimal sampling sites for repeat prostate biopsy: a recursive partitioning analysis of three-dimensional 26-core systematic biopsy, Eur Urol, 51, 675, 10.1016/j.eururo.2006.06.015 Scattoni, 2010, Biopsy schemes with the fewest cores for detecting 95% of the prostate cancers detected by a 24-core biopsy, Eur Urol, 57, 1, 10.1016/j.eururo.2009.08.011 Chen, 2000, Detailed mapping of prostate carcinoma foci: biopsy strategy implications, Cancer, 89, 1800, 10.1002/1097-0142(20001015)89:8<1800::AID-CNCR21>3.0.CO;2-D Bouyé, 2009, Transition zone and anterior stromal prostate cancers: zone of origin and intraprostatic patterns of spread at histopathology, Prostate, 69, 105, 10.1002/pros.20859 Haffner, 2009, Peripheral zone prostate cancers: location and intraprostatic patterns of spread at histopathology, Prostate, 69, 276, 10.1002/pros.20881 Chan, 1999, Follow-up of atypical prostate needle biopsies suspicious for cancer, Urology, 53, 351, 10.1016/S0090-4295(98)00510-X Schoenfield, 2007, The incidence of high-grade prostatic intraepithelial neoplasia and atypical glands suspicious for carcinoma on first-time saturation needle biopsy, and the subsequent risk of cancer, BJU Int, 99, 770, 10.1111/j.1464-410X.2006.06728.x Onik, 2009, Three-dimensional prostate mapping biopsy has a potentially significant impact on prostate cancer management, J Clin Oncol, 27, 4321, 10.1200/JCO.2008.20.3497 Ahmed, 2011, Characterizing clinically significant prostate cancer using template prostate mapping biopsy, J Urol, 186, 458, 10.1016/j.juro.2011.03.147 Scattoni, 2011, The optimal rebiopsy prostatic scheme depends on patient clinical characteristics: results of a recursive partitioning analysis based on a 24-core systematic scheme, Eur Urol, 60, 834, 10.1016/j.eururo.2011.07.036 Hambrock, 2012, Prospective assessment of prostate cancer aggressiveness using 3-T diffusion-weighted magnetic resonance imaging-guided biopsies versus a systematic 10-core transrectal ultrasound prostate biopsy cohort, Eur Urol, 61, 177, 10.1016/j.eururo.2011.08.042 Hoeks, 2012, Three-Tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers, Eur Urol, 62, 902, 10.1016/j.eururo.2012.01.047 Simmons, 2012, Detection, localisation and characterisation of prostate cancer by Prostate HistoScanning, BJU Int, 110, 28, 10.1111/j.1464-410X.2011.10734.x Brock, 2012, The impact of real-time elastography guiding a systematic prostate biopsy to improve cancer detection rate: a prospective study of 353 patients, J Urol, 187, 2039, 10.1016/j.juro.2012.01.063 Sano, 2011, Contrast-enhanced ultrasonography of the prostate: various imaging findings that indicate prostate cancer, BJU Int, 107, 1404, 10.1111/j.1464-410X.2010.09735.x Wolters, 2010, False-negative prostate needle biopsies: frequency, histopathologic features, and follow-up, Am J Surg Pathol, 34, 35, 10.1097/PAS.0b013e3181c3ece9 Epstein, 2012, Diagnosis of limited adenocarcinoma of the prostate, Histopathology, 60, 28, 10.1111/j.1365-2559.2011.03990.x Bostwick, 2007, Group consensus reports from the Consensus Conference on Focal Treatment of Prostatic Carcinoma, Celebration, Florida, February 24, 2006, Urology, 70, 42, 10.1016/j.urology.2007.07.037 Eggener, 2007, Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities, J Urol, 178, 2260, 10.1016/j.juro.2007.08.072 Moore, 2013, Image-guided prostate biopsy using magnetic resonance imaging–derived targets: a systematic review, Eur Urol, 63, 125, 10.1016/j.eururo.2012.06.004 Hadaschik, 2011, A novel stereotactic prostate biopsy system integrating pre-interventional magnetic resonance imaging and live ultrasound fusion, J Urol, 186, 2214, 10.1016/j.juro.2011.07.102 Pinto, 2011, Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging, J Urol, 186, 1281, 10.1016/j.juro.2011.05.078 Ukimura, 2012, Accuracy of 3D elastic registration system of prostate biopsy location by real-time 3D TRUS guidance with MR/TRUS image fusion: pilot phantom study, J Urol, 187, 1080, 10.1016/j.juro.2011.10.124 Lawrentschuk, 2009, Operator is an independent predictor of detecting prostate cancer at transrectal ultrasound guided prostate biopsy, J Urol, 182, 2659, 10.1016/j.juro.2009.08.036 Mozer, 2009, Mapping of transrectal ultrasonographic prostate biopsies: quality control and learning curve assessment by image processing, J Ultrasound Med, 28, 455, 10.7863/jum.2009.28.4.455 Hori S, Fuge O, Trabucchi K, Donaldson P, McLoughlin J. Can a trained non-physician provider perform transrectal ultrasound-guided prostatic biopsies as effectively as an experienced urologist? BJU Int. In press. http://dx.doi.org/10.1111/j.1464-410X.2012.11294.x. Rosario, 2012, Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study, BMJ, 344, d7894, 10.1136/bmj.d7894 Djavan, 2001, Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: results of a prospective European prostate cancer detection study, J Urol, 166, 856, 10.1016/S0022-5347(05)65851-X Carlsson, 2011, No excess mortality after prostate biopsy: results from the European Randomized Study of Screening for Prostate Cancer, BJU Int, 107, 1912, 10.1111/j.1464-410X.2010.09712.x Raber, 2008, Topical prilocaine-lidocaine cream combined with peripheral nerve block improves pain control in prostatic biopsy: results from a prospective randomized trial, Eur Urol, 53, 967, 10.1016/j.eururo.2007.09.005 Giannarini, 2009, Combination of perianal-intrarectal lidocaine-prilocaine cream and periprostatic nerve block for pain control during transrectal ultrasound guided prostate biopsy: a randomized, controlled trial, J Urol, 181, 585, 10.1016/j.juro.2008.10.002 Nam, 2010, Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy, J Urol, 183, 963, 10.1016/j.juro.2009.11.043 Loeb, 2012, Infectious complications and hospital admissions after prostate biopsy in a European randomized trial, Eur Urol, 61, 1110, 10.1016/j.eururo.2011.12.058 Zani, 2011, Antibiotic prophylaxis for transrectal prostate biopsy, Cochrane Database Syst Rev, CD006576 Zaytoun, 2011, Emergence of fluoroquinolone-resistant Escherichia coli as cause of postprostate biopsy infection: implications for prophylaxis and treatment, Urology, 77, 1035, 10.1016/j.urology.2010.12.067 Ruddick, 2011, Sepsis rates after ultrasound-guided prostate biopsy using a bowel preparation protocol in a community hospital, J Ultrasound Med, 30, 213, 10.7863/jum.2011.30.2.213 Wolf, 2008, Best practice policy statement on urologic surgery antimicrobial prophylaxis, J Urol, 179, 1379, 10.1016/j.juro.2008.01.068 Liss, 2011, Prevalence and significance of fluoroquinolone resistant Escherichia coli in patients undergoing transrectal ultrasound guided prostate needle biopsy, J Urol, 185, 1283, 10.1016/j.juro.2010.11.088 Steensels, 2012, Fluoroquinolone-resistant E. coli in intestinal flora of patients undergoing transrectal ultrasound-guided prostate biopsy—should we reassess our practices for antibiotic prophylaxis?, Clin Microbiol Infect, 18, 575, 10.1111/j.1469-0691.2011.03638.x Carignan, 2012, Increasing risk of infectious complications after transrectal ultrasound-guided prostate biopsies: time to reassess antimicrobial prophylaxis?, Eur Urol, 62, 453, 10.1016/j.eururo.2012.04.044 Taylor, 2012, Targeted antimicrobial prophylaxis using rectal swab cultures in men undergoing transrectal ultrasound guided prostate biopsy is associated with reduced incidence of postoperative infectious complications and cost of care, J Urol, 187, 1275, 10.1016/j.juro.2011.11.115 Batura, 2010, Adding amikacin to fluoroquinolone-based antimicrobial prophylaxis reduces prostate biopsy infection rates, BJU Int, 107, 760, 10.1111/j.1464-410X.2010.09715.x Adibi, 2012, Cost-effectiveness of standard vs intensive antibiotic regimens for transrectal ultrasonography (TRUS)-guided prostate biopsy prophylaxis, BJU Int, 110, E86, 10.1111/j.1464-410X.2011.10768.x